Third generation aromatase inhibitors (AI), mainly anastrozole and letrozole, have been used to increase predicted adult height (PAH) [1, 2] in boys with constitutional delay of growth and puberty (CDGP) [3], idiopathic short stature (ISS) [4–6], and growth hormone deficiency (GHD) [6, 7], as well as in testotoxicosis [8], and gynecomastia [9–11], but in girls only in the context of McCune-Albright syndrome [12–14] apart from one case report of a girl with a recurrent autonomous ovarian cyst [15]. The gene discussed is CYP19A1; the disease is McCune-Albright syndrome.